Browse > Article

$Site-Specific^{99m}$Tc-Labeling of Antibody Using Dihydrazinoph-thalazine (DHZ) Conjugation to Fc Region of Heavy Chain  

Jeong, Jae-Min (Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine)
Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University School of Medicine)
Paik, Chang-Hum (Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health)
Kim, Dae-Kee (Department of Pharmacy, Ewha Womans University)
Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine)
Chung, June-Key (Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine)
Lee, Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine)
Publication Information
Archives of Pharmacal Research / v.27, no.9, 2004 , pp. 961-967 More about this Journal
Abstract
The development of an antibody labeling method with $^{99m}$Tc is important for cancer imaging. Most bifunctional chelate methods for $^{99m}$Tc labeling of antibody incorporate a $^{99m}$Tc chelator through a linkage to lysine residue. In the present study, a novel site-specific $^{99m}$Tc labeling method at carbohydrate side chain in the Fc region of 2 antibodies (T101 and rabbit anti-human serum albumin antibody (RPAb)) using dihydrazinophthalazine (DHZ) which has 2 hydrazino groups was developed. The antibodies were oxidized with sodium periodate to pro-duce aldehyde on the Fc region. Then, one hydrazine group of DHZ was conjugated with an aldehyde group of antibody through the formation of a hydrazone. The other hydrazine group was used for labeling with $^{99m}$Tc. The number of conjugated DHZ was 1.7 per antibody. $^{99m}$Tc labeling efficiency was 46-85% for T101 and 67∼87% for RPAb. Indirect labeling with DHZ conjugated antibodies showed higher stability than direct labeling with reduced antibodies. High immunoreactivities were conserved for both indirectly and directly labeled antibodies. A biodistribution study found high blood activity related to directly labeled T1 01 at early time point as well as low liver activity due to indirectly labeled T101 at later time point. However, these findings do not affect practical use. No significantly different biodistribution was observed in the other organs. The research concluded that DHZ can be used as a site-specific bifunctional chelating agent for labeling antibody with $^{99m}$Tc. Moreover, $^{99m}$Tc labeled antibody via DHZ was found to have excellent chemical and biological properties for nuclear medicine imaging.edicine imaging.
Keywords
$^{99m}$Tc; Site-specific labeling; Radiopharmaceutical; Dihydralazine; Dihydrazinoph-thalazine; Antibody; Bifunctional chelating agent;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Babich, J. Wand Fischman, A . J., Effect of 'co-ligand' on the biodistribution of $^{99m}Tc$-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl. Med. Biol., 22, 25-30 (1995)   DOI   ScienceOn
2 Carrasquillo, J. A., Bunn, P. A., Keenan, A M., Reynolds, J. C., Schroff, R. W., Foon, K. A., Su, M. H., Gazdar, A. F., Mulshine, J. L., and Oldham, R. K., Radioimmunodetection of cutaneous T-cell lymphoma with In-111-labeled T101 monoclonal antibody. N. Engl. J. Med., 315, 673-680 (1986)   DOI   PUBMED   ScienceOn
3 Laverman, P., Behe, M., Oven, W. J. G., Willems, P. H. G. M., Corstens, F. H. M., Behr, T. M., and Boerman, O. C., Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjugate Chem., 15, 561-568 (2004)   DOI   ScienceOn
4 O'shannessy, D. J., Dobersen, M. J., and Quarles, R. H., A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties. Immunol. Lett., 8, 273-277 (1984).   DOI   ScienceOn
5 Paik, C. H., Phan, L. N. B., Hong, J. J., Sahami, M. S., Heald, S. C., Reba, R. C., Steigman, J., and Eckelman, W. C., The labeling of high affinity sites of antibodies with $^{99m}Tc$. Int. J. Nucl. Med. Biol., 12,3-8 (1985)   DOI   ScienceOn
6 Pettit, W. A., Deland, F. H., Bennett, S. J., and Goldenberg, D. M., Improved protein labeling by stannous tartrate reduction of pertechnetate. J. Nucl. Med., 21, 59-62 (1980)
7 Abrams, M. J., Juweid, M., tenKate, C. I., Schwartz, D. A., Hauser, M. M., Gaul, F. E., Fuccello, A. J., Rubin, R. H., Strauss, H. W., and Fischman, A. J., Technetium-99mhuman polyclonal IgG radiolabeled via the hydrazino nicotininamide derivativefor imaging focal sites of infection in rats. J. Nucl. Med., 31, 2022-2028 (1990)
8 Fichna, J. and Janecka, A., Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjugate Chem., 14, 3-17 (2003)   DOI   ScienceOn
9 Iznaga-Escobar, N., Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors a review of radiolabeling characteristics, quality control and in vitro stability studies. Appl. Radiat. lsot., 54, 399-406 (2001)   DOI   ScienceOn
10 Jeong, J. M., Hong, M. K., Lee, J., Son, M., So, Y., Lee, D. S., Chung, J.-K., and Lee, M. C.,$^{990m}Tc$-Neolactosylated human serum albumin for imaging the hepatic asialoglycoprotein receptor. Bioconjugate Chem., 15, 850-855 (2004)   DOI   ScienceOn
11 Mari-Buigues, J., Manes-Vinuesa, J., Garcia-Domenech, R., and Pous-Miralles, G., Spectrophotometric determination of hydralazine with 2-hydroxy-1-naphthaldehyde in pharmaceuticals. J. Pharm. Sci., 80, 690-692 (1991)   DOI   PUBMED
12 Nicholson, T. and Zubieta, J., Complexes of rhenium with benzolated and related ligands. Polyhedron, 7, 171-185 (1988)   DOI   ScienceOn
13 Schwartz, D. A., Abrams, M. J., Hauser, M. M., Gaul, F. E., Larsen, S. K., Rauth, D., and Zubieta, J. A., Preparation of hydrazino-mocified proteins and their use for the synthesis of Tc-99m-protein conjugates. Bioconjugate Chem., 2, 333-336 (1991)   DOI   PUBMED
14 Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976)   DOI   PUBMED   ScienceOn
15 Rodwell, J. D., Alvarez, V. L., lee, C., lopes, A. D., Goers, J. W. F., King, H. D., Powsner, H. J., and McKearn, T. J., Sitespecific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proc. Natl. Acad. Sci., U.S.A., 83, 2632-2636 (1986)   DOI   ScienceOn
16 Mather, S. J. and Ellison, E., Reduction-mediated technetium-99m labeling of monoclonal antibodies. J. Nucl. Med., 31, 692-697 (1990)
17 Fritzberg, A. R., Abrams, P. G., Beumier, P. L., Kasina, S., Morgan, C., Rao, T. N., Reno, J. M., Sanderson, J. A., Srinivasan, A., Wilber, S., and Vanderheyden, J. L., Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc. Natl. Acad. Sci., U.S.A., 85, 4025-4029 (1988)   DOI   ScienceOn
18 Hinkle, G. H., Loesch,J. A., Hill, T. L., Lefevre, S. R., and Olsen, J. O., Indium-111-monoclonal antibodies in radioimmunos-cintigraphy. J. Nucl. Med. Technol., 18, 16-28 (1990)
19 Kasina, S., Sanderson, J. A, Fitzner, J. N., Ananthachari, S., Rao, T. N., Hobson, L. j., Reno, J. M., Axworthy, D. B., Beaumier, P. L., and Fritzberg, A. R., Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate). Bioconjugate Chem., 9, 108-117(1998)   DOI   ScienceOn
20 Babich, J. W., Solomon, H., Pike, M. C., Kroon, D., Graham, W., Abrams,M. J., Tompkins, R. G., Rubin, R. H., and Fischman, A. J., Technetium-99m-labeled hydrazine nicotinamide derivatized chemotactic peptide analogues for imaging focal sites of bacterial infection. J. Nucl. Med., 34, 1964-1974 (1993)
21 Hnatowich, D. J., Mardirossian, G., Ruscowski, M., Fogarasi, M., Virzi, F., and Winnard, P., Directly and indirectly technetium-99m-labeled antibodies - A comparison of in vitro and animal in vivo properties. J. Nucl. Med., 34, 109-119 (1993)
22 Riccabona, G. and Decristoforo C., Peptide targeted imaging of cancer. Cancer Biother. Radiopharm., 18, 675-687 (2003)   DOI   ScienceOn